Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts.

During the past decade, Dana Farber Cancer Institute/Brigham and Women's Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 27 clinical trials were completed, i.e. on average, 180% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 13 clinical trials were completed. i.e. 325% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dana Farber Cancer Institute/Brigham and Women's Hospital" #1 sponsor was "Medical College of Wisconsin" with 13 trials, followed by "National Heart, Lung, and Blood Institute (NHLBI)" with 7 trials sponsored, "Dana-Farber Cancer Institute" with 6 trials sponsored, "Massachusetts General Hospital" with 2 trials sponsored and "Beth Israel Deaconess Medical Center" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana Farber Cancer Institute/Brigham and Women's Hospital" #1 collaborator was "Blood and Marrow Transplant Clinical Trials Network" with 20 trials as a collaborator, "National Cancer Institute (NCI)" with 19 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 15 trials as a collaborator, "National Marrow Donor Program" with 13 trials as a collaborator and "Brigham and Women's Hospital" with 4 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Dana Farber Cancer Institute/Brigham and Women's Hospital" are "Breast Cancer" (9 trials), "Multiple Myeloma" (4 trials), "Prostate Cancer" (4 trials), "Acute Leukemia" (3 trials) and "Leukemia, Myelocytic, Acute" (3 trials). Many other conditions were trialed in "Dana Farber Cancer Institute/Brigham and Women's Hospital" in a lesser frequency.

Most popular intervention types in "Dana Farber Cancer Institute/Brigham and Women's Hospital" are "Drug" (30 trials), "Biological" (7 trials), "Procedure" (6 trials), "Radiation" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (5 trials), "Methotrexate" (4 trials), "Paclitaxel" (4 trials), "Tacrolimus" (4 trials) and "Mycophenolate Mofetil" (3 trials). Other intervention names were less common.

The vast majority of trials in "Dana Farber Cancer Institute/Brigham and Women's Hospital" are 38 trials for "All" genders, 4 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Dana Farber Cancer Institute/Brigham and Women's Hospital". undefined are not yet recruiting, 5 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Dana Farber Cancer Institute/Brigham and Women's Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Dana Farber Cancer Institute/Brigham and Women's Hospital, 4 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".